-
2005
Invent Medic is formed to further develop Jan Clarén’s innovative product TVS that relieves female incontinence.
-
2006-2007
Further development together with Lars-Olof Henriksson provides an anatomically functional product.
-
2008
The first patent application is filed.
-
2009
The first prototypes are developed for clinical evaluation.
-
2010
Patent approval is obtained in Sweden, and Lars Persson is engaged as chairman of the board.
-
2011
Small-scale production begins.
-
2012-2013
Discussions with market stakeholders indicate interest in a CE marked product.
-
2014
The company decides to launch products on its own, and Karin Bryder is appointed as CEO.
-
2015
Grants of 0.5 MSEK are received from the government agency Vinnova for market research.
A directed share issue of approximately 4 MSEK is conducted.
-
2016
A share issue of 9 MSEK is conducted, and the company is listed on Aktietorget (later renamed to Spotlight Stock Market).
Large-scale production is ensured through the leading European manufacturer TMRubber.
Patent approval is obtained in the United States.
-
2017
Patent approval is obtained in Europe.
Share issue of 10.2 MSEK is conducted.
-
2018
The clinical study with Efemia is completed with significant positive results.
A share issue of 19.3 MSEK is conducted.
Efemia receives CE marking and is launched in Sweden under the Arcamea brand name.
A post-launch user study is initiated in collaboration with Aller Media.
-
2019
Efemia is launched in Denmark, Norway, the UK and Germany.
The work with evaluating the next Invent Medic product is intensified.
Invent Medic submits offers for Efemia in public procurements processes in Sweden.
Västra Götaland becomes the first health care region in Sweden to order Efemia in accordance with an agreement valid until a potential public procurement process is finalised.
